1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies

1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies


PER Pulse™ Recap

Resources

Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies
Earn up to 1.5 AMA PRA Category 1 Credits™
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting. 

PER Pulse™ Recap
PER Pulse™ Recaps for Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies


PER Pulse™ Recap

 

1 of 3
PER Pulse Recap

The Expanding Therapeutic Toolbox for Patients With Chronic Lymphocytic Leukemia

The 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies, held 4-5 November, 2016, was convened to present information from an expert faculty on recent advances in the fields of myeloma and lymphoma, including chronic lymphocytic leukemia (CLL), and to discuss the integration of new approaches in the clinic. This first of 3 PER Pulse™ Recaps from the conference focuses on treatment of elderly patients and on new targeted agents for patients with relapsed/refractory CLL.

The first case in this module involved a 69-year-old patient with CLL and no del(17p). The expert faculty recommendation was BR (bendamustine and rituximab) based on the CLL10 trial showing similar progression-free survival between BR and FCR (fludarabine, cyclophosphamide, and rituximab) in patients age >65 years, but a more favorable safety profile of BR compared with FCR. Other appropriate options are obinutuzumab/chlorambucil or single-agent ibrutinib. In the case of a patient with del(17p), ibrutinib would be the treatment of choice.

In the second case, a 64-year-old patient with CLL received FCR, with relapse approximately 6 years later. The recommendation of the expert faculty was a B-cell signaling inhibitor such as ibrutinib, or the combination of idelalisib plus rituximab. If the patient had del(17p), these would remain appropriate; the BCL-2 inhibitor venetoclax is also approved in this setting and provides another treatment option.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual European Congress on Hematology™, including downloadable slides from the meeting.



2 of 3
PER Pulse™ Recap

Expanding Options for Patients With Multiple Myeloma

The 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies, held 4-5 November, 2016, was convened to present information from an expert faculty on recent advances in the fields of myeloma and lymphoma, including chronic lymphocytic leukemia, and to discuss the integration of new approaches in the clinic. This second of 3 PER Pulse™ Recaps from the conference focuses on recent data on treatment of patients with multiple myeloma (MM).

In a transplant-eligible patient with MM, expert recommendation is induction therapy with a triplet regimen such as VRd (bortezomib, lenalidomide, and low-dose dexamethasone). After autologous stem cell transplant (ASCT), maintenance therapy with lenalidomide is a standard approach. The recent phase 3 StaMINA trial showed that intensification of therapy, such as maintenance VRd or a second ASCT, did not improve outcomes.

For patients with relapsed/refractory MM, there is a rapidly expanding array of agents available, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and histone deacetylase inhibitors. The exact choice of regimen will depend on prior therapies, duration of response, and comorbidities. In the case challenge for this module, the patient had progressed during maintenance lenalidomide, and the expert recommendation was to offer a proteasome-inhibitor‒based combination regimen.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual European Congress on Hematology™, including downloadable slides from the meeting.


3 of 3
PER Pulse™ Recap

Therapeutic Options for Patients With Relapsed Lymphoma

The 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies, held 4-5 November, 2016, was convened to present information from an expert faculty on recent advances in the fields of myeloma and lymphoma, including chronic lymphocytic leukemia, and to discuss the integration of new approaches in the clinic. This third of 3 PER Pulse™ Recaps from the conference focuses on treatment for patients with relapsed follicular lymphoma (FL) or Hodgkin lymphoma (HL).

The first case discussed in this module involved a patient with FL who relapsed 22 months after treatment with R-CVP (rituximab + cyclophosphamide, vincristine, and prednisone). Expert recommendation for this patient was BR (bendamustine + rituximab); additionally, bendamustine plus obinutuzumab followed by maintenance obinutuzumab has recently been approved for patients with relapsed/refractory FL.

In the second case, a patient with classical HL (cHL) had undergone several lines of therapy, including autologous stem cell transplantation and brentuximab vedotin. The immune checkpoint inhibitor nivolumab has been approved in this setting and is the recommendation of the expert faculty.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual European Congress on Hematology™, including downloadable slides from the meeting.

 







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By